Clinical Trials · NCT02663908
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 545
- Start date
- Apr 2016
- Locations
- 133 sites, 12 countries
- Primary endpoint
- Time From Randomization to the First Confirmed (Adjudicated) Occurrence of the Composite Major Adverse Cardiovascular Event (MACE) Endpoint; Percentage of Observed Subjects With Outcome Measure Events During the Trial